52 Einträge gefunden

1. VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience

   1. Ghandili, Susanne
   2. Alihodzic, Dzenefa
   3. Wiessner, Christian
   4. Bokemeyer, Carsten
   5. Weisel, Katja
   6. Leypoldt, Lisa B

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
2. Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients With Relapsed/Refractory Multiple Myeloma: Final Data From the Phase 2 ELOQUENT-3 Trial

   1. Weisel, Katja
   2. Dimopoulos, Meletios A
   3. San-Miguel, Jesús
   4. Paner, Agne
   5. Engelhardt, Monika
   6. Taylor, Fiona
   7. Lord-Bessen, Jennifer

   2023 - Forschungsinformationssystem des UKE - frei zugänglich
3. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

   1. D'Souza, Anita
   2. Shah, Nina
   3. Rodriguez, Cesar
   4. Voorhees, Peter M
   5. Weisel, Katja
   6. Bueno, Orlando F
   7. Pothacamury, Rajvineeth K

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
4. Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

   1. Leleu, Xavier
   2. Martin, Thomas
   3. Weisel, Katja
   4. Schjesvold, Fredrik
   5. Iida, Shinsuke
   6. Malavasi, Fabio
   7. Manier, Salomon

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
5. Carfilzomib 56 mg/m2 twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison

   1. Weisel, Katja
   2. Nooka, Ajay K
   3. Terpos, Evangelos
   4. Spencer, Andrew
   5. Goldschmidt, Hartmut
   6. Dirnberger, Franziska
   7. DeCosta, Lucy

   2022 - Forschungsinformationssystem des UKE
6. COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress

   1. Modemann, Franziska
   2. Ghandili, Susanne
   3. Schmiedel, Stefan
   4. Weisel, Katja
   5. Bokemeyer, Carsten
   6. Fiedler, Walter

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
7. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial

   1. Lonial, Sagar
   2. Popat, Rakesh
   3. Hulin, Cyrille
   4. Jagannath, Sundar
   5. Oriol, Albert
   6. Richardson, Paul G
   7. Facon, Thierry

   2022 - Forschungsinformationssystem des UKE
8. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

   1. Weisel, Katja
   2. Krishnan, Amrita
   3. Schecter, Jordan M
   4. Vogel, Martin
   5. Jackson, Carolyn C
   6. Deraedt, William
   7. Yeh, Tzu-Min

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
9. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

   1. Weisel, Katja
   2. Martin, Thomas
   3. Krishnan, Amrita
   4. Jagannath, Sundar
   5. Londhe, Anil
   6. Nair, Sandhya
   7. Diels, Joris

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
10. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy

    1. Pape, Luca Julius
    2. Hambach, Julia
    3. Gebhardt, Anna Josephine
    4. Rissiek, Björn
    5. Stähler, Tobias
    6. Tode, Natalie
    7. Khan, Cerusch

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
11. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics

    1. Richardson, Paul G
    2. Schjesvold, Fredrik
    3. Weisel, Katja
    4. Moreau, Philippe
    5. Anderson, Larry D
    6. White, Darrell
    7. Rodriguez-Otero, Paula

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
12. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma

    1. Martin, Thomas
    2. Krishnan, Amrita
    3. Yong, Kwee
    4. Weisel, Katja
    5. Mehra, Maneesha
    6. Nair, Sandhya
    7. Qi, Keqin

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
13. Real-world study on adoption of standard-of-care for transplant-eligible newly diagnosed multiple myeloma patients between 2017 and 2020/2021 across France, Germany, Spain, and Italy

    1. Weisel, Katja
    2. Wadlund, Astrid Ottosson
    3. Gungor, Guntug
    4. Dergarabetian, Eileen
    5. Pacheco, Cécile
    6. Masurkar, Nihar
    7. Rodriguez-Otero, Paula

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
14. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    1. Mateos, Maria-Victoria
    2. Weisel, Katja
    3. De Stefano, Valerio
    4. Goldschmidt, Hartmut
    5. Delforge, Michel
    6. Mohty, Mohamad
    7. Cavo, Michele

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
15. COVID-19 and seasonal influenza: a comparative analysis in patients with hematological malignancies

    1. Modemann, Franziska
    2. Niederwieser, Christian
    3. Weisel, Katja
    4. Bokemeyer, Carsten
    5. Fiedler, Walter
    6. Ghandili, Susanne

    2022 - Forschungsinformationssystem des UKE
16. Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells

    1. Hambach, Julia
    2. Fumey, William
    3. Stähler, Tobias
    4. Gebhardt, Anna Josephine
    5. Adam, Gerhard
    6. Weisel, Katja
    7. Koch-Nolte, Friedrich

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
17. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

    1. Landgren, Ola
    2. Weisel, Katja
    3. Rosinol, Laura
    4. Touzeau, Cyrille
    5. Turgut, Mehmet
    6. Hajek, Roman
    7. Mollee, Peter

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
18. Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

    1. Krohn, Steffen
    2. Boje, Ammelie Svea
    3. Gehlert, Carina Lynn
    4. Lutz, Sebastian
    5. Darzentas, Nikos
    6. Knecht, Henrik
    7. Herrmann, Dietrich

    2022 - Forschungsinformationssystem des UKE - frei zugänglich
19. MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1-3 Prior Lines of Therapy (LOT)

    1. Hillengass, Jens
    2. Cohen, Adam D
    3. Delforge, Michel
    4. Einsele, Hermann
    5. Goldschmidt, Hartmut
    6. Weisel, Katja
    7. Raab, Marc-Steffen

    2022 - Forschungsinformationssystem des UKE
20. Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

    1. Dimopoulos, Meletios
    2. Weisel, Katja
    3. Moreau, Philippe
    4. Anderson, Larry D
    5. White, Darrell
    6. San-Miguel, Jesus
    7. Sonneveld, Pieter

    2021 - Forschungsinformationssystem des UKE - frei zugänglich